{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.17","value":"1.3"},{"groupId":"OG001","spread":"1.35","value":"3.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"83"},{"groupId":"OG001","value":"39"}],"units":"Participants"}],"description":"Subjects will be randomized to F-627 or Placebo at 2:1 ratio. About 24 hours after chemotherapy, subjects will either receive 20mg fixed dose F-627 or Placebo. The subject's absolute neutrophil count (ANC) will be monitored each day post chemotherapy administration until the ANC level exceeds 2.0x10\\^9/L, then the value will be monitored every three days until the next chemotherapy cycle is entered. The duration of grade 4 neutropenia (ANC \\<0.5x10\\^9/L) in this cycle is the primary efficacy endpoint.","dispersionType":"Standard Deviation","groups":[{"description":"F-627, 20 mg fixed dose pre-filled syringe, dosed Day 2 of each of 4 chemotherapy cycles.","id":"OG000","title":"F-627"},{"description":"Placebo, pre-filled syringe administered Day 2 of the first chemotherapy cycle; and F-627, 20 mg fixed dose pre-filled syringe administered Day 2 of each of the following 3 chemotherapy cycles.","id":"OG001","title":"Placebo"}],"paramType":"MEAN","reportingStatus":"POSTED","timeFrame":"The first of 4, 21 Day Chemotherapy Cycles, an average of 3 weeks","title":"The Duration in Days of Grade 4 (Severe) Neutropenia Observed in Chemotherapy Cycle 1 in Comparison to Placebo","type":"PRIMARY","unitOfMeasure":"days"}